Physician profile
Amy Cox
NPI 1215966544
$12,442.02
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,795 · 2022: $7,390 · 2023: $168 · 2024: $90.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,272.60 | 2021-2022 | |
| Genentech USA, INC. | $3,394.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $432.82 | 2021-2024 | Libtayo |
| Seagen INC. | $413.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $302.39 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $250.30 | 2021 | |
| Eisai INC. | $186.02 | 2021 | |
| Janssen Biotech, INC. | $181.67 | 2021-2022 | |
| Myovant Sciences INC. | $124.11 | 2022 | |
| Glaxosmithkline, LLC. | $124.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $123.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $121.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $104.49 | 2021 | |
| Celgene Corporation | $98.33 | 2021 | |
| Rigel Pharmaceuticals, INC. | $82.40 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.74 | 2022 | |
| Beigene USA, INC. | $64.40 | 2023 | Brukinsa |
| Genentech, INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.